Incyte Corp
INCYHealthcare|Biotechnology|USA
$93.59
-1.27 (-1.34%)
DCF (FCF)
$55.64
Tangible Book
$24.78
Graham Number
$61.53
Earnings Power
$50.38
Upcoming Data Readouts (112)
May 2026
Est. completion
P1Healthy Participants
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
NCT07448155n=72
Jun 2026
Est. completion
P1Acute Lymphoblastic Leukemia
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
NCT02494882n=12
Jun 2026
Est. completion
P2Well-differentiated/Dedifferentiated Liposarcoma
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
NCT04438824n=42
Jun 2026
Est. completion
P2Moderate to Severe Asthma
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
NCT05851443n=240
Jun 2026
Est. completion
P2Diffuse Large B Cell Lymphoma
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
NCT05757219n=27
Jun 2026
Est. completion
P2Myelofibrosis
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
NCT04640025n=18
Jul 2026
Est. completion
P2Intrahepatic Cholangiocarcinoma
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
NCT06728410n=38
Jul 2026
Est. completion
P1P2Chronic Graft-versus-host-disease
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
NCT06843408n=30
Jul 2026
Est. completion
P3Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618n=240
Jul 2026
Est. completion
P2Advanced Solid Tumor
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
NCT05879822n=73
Aug 2026
Est. completion
Graft Vs Host Disease
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
NCT06649201n=40
Aug 2026
Est. completion
P3NonSegmental Vitiligo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NCT06548360n=180
Sep 2026
Est. completion
P3Diffuse Large B-cell Lymphoma
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092n=899
Sep 2026
Est. completion
P1Breast Cancer
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
NCT06488378n=20
Sep 2026
Est. completion
P1Acute Lymphoblastic Leukemia
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
NCT03571321n=15
Sep 2026
Est. completion
P1Graft Vs Host Disease
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
NCT06008808n=41
Sep 2026
Est. completion
P2Cutaneous Squamous Cell Carcinoma
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
NCT05888844n=63
Sep 2026
Est. completion
P1P2Soft Tissue Sarcoma
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
NCT04577014n=98
Sep 2026
Est. completion
P2P3Acute Lymphoblastic Leukemia
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT03117751n=790
Oct 2026
Est. completion
P2Hidradenitis Suppurativa
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
NCT04414514n=24
Awaiting Results (25)
Trials past primary completion date but still active — data readout may be imminent.
May 2026
P1P2
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
NCT06873789Apr 2026
P2
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
NCT04463771Apr 2026
P1
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
NCT05743595Apr 2026
P3
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
NCT05429268Mar 2026
P3
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471Feb 2026
P3
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445Dec 2025
P2
Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)
NCT04160546Nov 2025
P1P2
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
NCT04551131